Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more

Recent & Breaking News (NDAQ:GLYC)

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Business Wire 11 hours ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, PFIE, GLYC on Behalf of Shareholders

Accesswire 1 day ago

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating GlycoMimetics, Inc. Merger

Newsfile 2 days ago

Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders

Business Wire 2 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PR Newswire 2 days ago

GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders

Business Wire 2 days ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Business Wire 2 days ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Business Wire 2 days ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

Business Wire July 25, 2024

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Business Wire June 4, 2024

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

Business Wire May 29, 2024

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Business Wire May 6, 2024

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Business Wire April 25, 2024

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Business Wire March 27, 2024

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Business Wire March 13, 2024

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Business Wire February 26, 2024

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire February 12, 2024

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Business Wire January 4, 2024

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

GlobeNewswire January 3, 2024

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Business Wire December 10, 2023